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Abstract: In medical research the visualization of drug carrier accumulation and release of the loaded
drugs in vivo is an important field. In this work, two protein-stabilized gold nanoclusters (Au NCs) as
effective fluorescent reporters (FRs) were investigated for labeling of biocompatible chitosan-modified
hyaluronic acid based nanocarriers having two different structures. The colloid stability of the labeled
carriers was studied by dynamic light scattering and Zeta potential measurements, while the changes
in the fluorescence of the lysozyme- (LYZ) and bovine serum albumin (BSA)-stabilized Au NCs were
analyzed by spectrofluorimetry and confocal fluorescent microscopy. We found that the labeling was
effective with a wide range of marker:carrier mass ratios, and the fluorescence of the NCs and the
colloid stability of the complexes were retained. Labeling during preparation and subsequent labeling
were compared, and based on composition (nanocluster:carrier mass ratio) and structure of the
complex systems we preferred the latter method, as it left the Au NCs free for further modifications.
Considering both marker:carrier mass ratios and emission intensities, the LYZ-stabilized Au NCs
proved to be better labels. The core-shell type carrier formulations showed increased fluorescence
with LYZ-stabilized NCs, presumably from aggregation induced emission.
Keywords: gold nanoclusters; fluorescence; colloidal drug carriers; fluorescence labeling; hyaluronic
acid; chitosan; aggregation-induced emission
1. Introduction
The polymer-based nanostructured drug carrier systems play an increasing role in the fields
of biomedicine, nanomedicine, and pharmacy [1]. By using them, we can prolong and increase
the efficacy of the drugs; furthermore, it is possible to introduce therapeutic compounds which are
significantly hampered by the specific properties of the given active ingredient. (e.g., hydrophilicity,
charge, degradation) [2,3]. The biocompatibility and biodegradability are crucial properties because
they ensure that the carriers do not cause inflammation or accumulate in the organs and tissues after
releasing the drug load. Polysaccharides such as chitosan (Chit) and hyaluronan (HyA) are promising
materials in this field due to their advantageous characteristics [1,4,5]. Accordingly, they are used
in several forms (hydrogels, films, and nanoparticles (NPs)) and applications [2,6–8]. The precise
combination of these oppositely charged polysaccharides can produce finely tuned NPs, which can be
used for gene delivery, or for loading different drugs and cancer therapeutics [9,10].
In medical applications, the noninvasive detection and monitoring of colloidal carrier accumulation
in tissues is an important aspect, especially in cancer therapy. The selective release of drugs can be
observed in vivo, without removing tissues in harmful operations and sacrificing the test animal in
the appropriate phases of clinical tests [11–14]. There is an increasing number of publications in the
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literature reporting the possible use of organic dye molecules (e.g., cyanine derivatives) as potential
fluorescent reporters (FRs) for drug delivery monitoring. These materials must meet a number of
requirements, such as suitable brightness and solubility, good photo- and chemical stability, low toxicity
as well as the absorption and emission are suggested to be in the red and near infrared (NIR) region
(~600–900 nm) where biological objects have a negligible autoabsorption and autofluorescence.
Highly fluorescent gold nanoclusters (Au NCs) are widely used sub-nanometer sized objects
in chemical and medical fields due to their numerous special characteristics [15,16]. Depending on
their size/structure, the type of stabilizing (bio)ligands as well as their fabrication methods, several
Au NCs with a wide range of properties, like tunable fluorescence in visible light and NIR region
can be prepared [17–20]. There is a growing interest in these materials in biological applications
like in analytical methods [17,20–22] as well as in theranostics [11,14,16,17] and fluorescent labeling
of cells and tissues [12,15,17,23,24]. In contrast to the previously mentioned organic dye molecules
or the intensively studied quantum dots (QDs) these Au NCs possess less toxic feature and better
photochemical stability as well. In biological applications it is imperative that the stabilizing ligands and
the whole nanocluster are biocompatible to prevent harmful side effects during and after administration.
Generally, nucleic acids, amino acids, peptides, and proteins are applied as reducing and stabilizing
ligands to synthesize fluorescent Au NCs via a one-pot “green” synthetic approach [18,19,22,25–29].
So far, the fluorescent Au NCs were mainly used for cell labeling [12,15,17,24], and as drug carriers in
cancer therapy [11,14–16,30], but the labeling of conventional nanosized drug carrier formulations was
very rare [14,18,23].
The main motivation of this work was to investigate the limitations of the applicability of
protein-stabilized red-emitting Au NCs as effective FRs for labeling of polysaccharide-based colloidal
drug delivery systems. Namely, bovine serum albumin- (BSA-Au NCs) and lysozyme-directed
(LYZ-Au NCs) Au NCs as fluorescent markers and chitosan-modified hyaluronic acid based colloidal
nanoparticles as drug carriers with tocopherol as a test drug were fabricated reproductively according
to our previous works [10,29]. On one hand, the quantitative evaluation of the Au NC–polymer carrier
interaction was accomplished and the formation, the size distribution and stability of the fluorescent
metal cluster/polymer carrier complexes were also investigated at several cluster:carrier mass ratios.
The fluorescent labeling of colloidal carriers was carried out in two different ways. Based on these
studies we tried to emphasize that the efficacy of the fluorescent labeling can be greatly controlled by
the applied cluster:carrier mass ratio, the type of the protein-stabilized Au NCs as well as the type and
the structure of polysaccharide-based colloidal drug carriers NPs.
2. Materials and Methods
2.1. Materials
The following materials were used for the preparation of fluorescent Au NCs: bovine serum
albumin (BSA, ≥90%, Sigma-Aldrich, Budapest, Hungary), lysozyme (LYZ, ≥90%, Sigma-Aldrich),
HAuCl4·3H2O (Sigma-Aldrich), and sodium hydroxide (≥99%, Molar Chemicals, Halásztelek,
Hungary). In all cases, the stock solutions were freshly prepared using Milli-Q ultrapure water
(18.2 MΩ cm at 25 ◦C). High-molecular-weight chitosan (HMW Chit, 310–375 kDa, >75% deacetylated,
Sigma-Aldrich, Budapest, Hungary) and hyaluronic acid sodium salt (HyA, 1.5–1.8 × 106 Da, ≤1%
protein, Sigma-Aldrich, Budapest, Hungary) were used for the preparation of the nanoparticles, with
Tripolyphosphate (TPP, for BOD determination, Merck KGaA, Darmstadt, Germany) as cross-linking
agent. Acetic acid (AcOH, ≥99.5%, Erdőkémia Co, Tolmács, Hungary) and sodium hydroxide were
used for controlling the pH during synthesis, and±-α-tocopherol (TCP,≥96%, Sigma-Aldrich, Budapest,
Hungary) was used as a model drug. All solvents and reagents used for preparation were of analytical
grade and no further purifications were carried out.
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2.2. Preparation and Characterization of Protein-Stabilized Au NCs
The preparation of protein-stabilized Au NCs was carried out based on the well-known template
method [29,31]. Briefly, 500 µL of 0.1 M HAuCl4 solution was added into the adequate volume of
aqueous solution of 0.4 g LYZ or 0.2 g BSA protein, separately. The final gold content was 1 mM and the
applied weight ratios were 20:1 and 15:1 in the case of LYZ and BSA, respectively. The pH was adjusted
to pH = 12 with 1 M NaOH solution and the reaction mixture was kept at 37 ± 0.1 ◦C for 24 h. During
the synthesis, the intensive yellow color of the HAuCl4 changed to light brown, which indicated the
formation of the ultrasmall gold nanohybrid systems. Before the exact structural characterization
and further applications, the dispersions were purified by dialysis for 24 h using general cellulose
dialysis membrane with 12 kDa cut-off. The emission features of the prepared Au NCs were studied by
spectrofluorimetry (λex = 350 nm and slit = 3 nm) using a Jobin Yvon Fluoromax-4 spectrofluorometer
(Horiba, Retsch Technology GmbH, Haan, Germany) while the size of the NCs was measured by a
FEI Tecnai G2 20 X-Twin high-resolution transmission electron microscope (HRTEM) (Auroscience
Ltd, Budapest, Hungary) applying an accelerating voltage of 220 kV. The final metal content was
determined by the ICP-MS technique applying dissolution of the nanodispersion by hot aqua regia with
1 h contact time. The measurements were done using an Agilent 7700x inductively coupled plasma
mass spectrometer (ICP-MS). The matrix-matched multipoint calibration was performed applying
the IV-ICPMS-71C certified calibration standard (Inorganic Ventures), while the ICP-MS plasma and
interface parameters were optimized via standard tuning solutions (G1820-60410, Agilent). The data
was evaluated using Agilent Mass Hunter software. The oxidation state of the Au was determined
by X-ray photoelectron spectroscopy (XPS) studies using a SPECS instrument, which was equipped
with a PHOIBOS 150 MCD 9 hemispherical analyzer. The conformational changes in the proteins
were analyzed by Fourier-transform infrared (FT-IR) and Circular dichroism (CD) before and after
cluster synthesis. The spectra were recorded on a BIO-RAD Digilab Division FTS-65 A/896 infrared
spectrometer equipped with a single-reflection diamond Attenuated Total Reflectance (ATR) accessory
(Harrick’s Meridian®SplitPea) and an ABL&E-JASCO J-1100 CD spectrometer (ABL&E-JASCO,
Budapest, Hungary) in a 1 cm quartz cuvette between 190 and 300 nm. To determine the kinetic
stability of the Au NCs based on the values of their hydrodynamic diameter and ζ-potential, a Malvern
Nano ZS ZEN 4003 (PCT, Mosonmagyaróvár, Hungary) Zetasizer apparatus was employed with a
He-Ne laser (λ = 633 nm) at 25 ± 0.1 ◦C.
2.3. Preparation of Polysaccharide-Based Colloidal Drug Carrier Particles
The preparation of the Chit-HyA drug carriers was reproduced from our previous work, with slight
changes [10]. The TPP cross-linked Chit-HyA NPs (labeled as type II) were fabricated using
the ionic gelation method. First, the stock solutions of HMW Chit (cChit = 2 mg/mL) and HyA
(cHyA = 0.615 mg/mL) were prepared by dissolving the polysaccharides in appropriate solvents (2 vol%
AcOH for Chit and MilliQ water for HyA). The Chit solution was then diluted to 0.727 mg/mL with
buffering to pH = 4.55–4.60 using 2 vol% AcOH and 1 M NaOH solutions, and the HyA stock solution
was simply diluted to 15.4 µg/mL. Then 8.125 mL of the HyA solution was mixed with 1.25 mL of
2 mg/mL TPP solution (Chit:TPP mass ratio was 2:1). To obtain NPs, the full amount of HyA-TPP
mixture was added in one step to 6.875 mL of diluted Chit solution under strong magnetic stirring.
The final obtained Chit:HyA mass ratio was 40:1. For the Chit-TPPcore–HyAshell NPs (labeled as type III)
the core NPs (Chit-TPPcore) were prepared in the first step. Here 1.25 mL of TPP solution (c = 2 mg/mL)
was added to heavily stirred 6.875 mL of buffered HMW Chit solution (cChit = 0.727 mg/mL) in 50 µL
portions, waiting five seconds for mixing before the following addition of TPP. The formed suspension
was stirred for a few minutes before the next step. To make the HyA coating, 8.125 mL HyA solution
(c= 15.4 µg/mL and 61.5 µg/mL) was mixed to the vigorously stirred Chit-TPPcore suspension, resulting
in Chit:HyA mass ratios of 40:1 and 10:1, respectively.
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2.4. Fluorescent Labeling of Nanocarriers
The labeling process was carried out using two methods: (i) addition of the labeling agents during
the preparation of colloidal carriers or (ii) subsequent labeling of the preformed composites. In the
first method, different amounts of Au NC dispersions were added to the synthesis mixture containing
negatively charged substances (HyA and/or TPP), and then added to the buffered Chit solution. In the
latter case, the Au NCs were added to previously prepared NP dispersions, labeling the surface of
carriers utilizing electrostatic interaction between the polysaccharides and Au NCs. The labeling was
the same for carriers containing TCP as well.
2.5. Characterization of the Fluorescent Labeling Procedure
The pure drug carriers and the labeled samples were characterized using dynamic light scattering
(DLS) for determination of particle size and size distribution, and Zeta potential measurements for
evaluating stability in all cases. The measurements were performed on a HORIBA SZ-100 NanoParticle
Analyzer (Retsch Technology GmbH, Haan, Germany). To determine the charge neutralization point
of each carrier–Au NC pair, 1 mL of drug carrier dispersion was first diluted to 3 mL with ultrapure
water, and then increasing amounts of BSA- or LYZ-Au NC were added to obtain a series of samples
with different carrier-Au NC mass ratios. (These labeled complexes served as titration points for the
labeling process, with mass ratios before, during and after charge neutralization.) The six titrations
were also investigated using DLS and Zeta potential measurements. The point of zero charge for
every titration was calculated using non-linear regression method, using the six-parameter Boltzmann
equation [32,33]:
y =
A1 ∗ x + A2
1 + exp
(
x−A4
A3
) + A5 ∗ x + A6,
where A1–A6 are fitting parameters. This method was not suitable for the 40:1 Chit-HyA type III +
LYZ-Au NC titration, because the fitted function always gave unsatisfactory y values close to x = 0,
so here the four-parameter Boltzmann equation was used instead:
y = A2 +
A1−A2
1 + exp
(
x−A3
A4
) ,
where A2 is the top value, A1 is the bottom value, A3 is the x value of the inflection point (half the
distance between A2 and A1) and A4 is the range where the y value changes from A2 to A1. After getting
the parameters of the functions, the point of zero charge was calculated for every titration, and then
they were compared.
The labeled complexes were investigated using fluorescent microscopy (Leica DM IL LED inverted
laboratory microscope), where morphology of the labeled carriers, fluorescence emission intensity and
distribution were determined. For this measurement, the samples were prepared on microscope slides
using a stamping method. In our case the complexes chosen from the titration process were placed on
the slides, then a small piece of fabric (stamp) was placed on the droplet. This method allowed the
labeled carriers to congregate in the crevices between the fibers of the stamp during the drying step,
resulting in stronger, more distinguishable fluorescence.
3. Results
3.1. Characterization of BSA- and LYZ-Au NCs
As the red-emitting Au NCs are well-known fluorescent materials, several publications can
be found in the literature related to the optimization of the synthesis protocols, as well as the
characterizations. In this article, we decisively focused on their applications as FRs of drug carrier
systems, the detailed description of their optical and structural properties can be found in our previous
articles [29,34].
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The prepared Au NCs showed intensive red emissions (λem~650 nm) using 350 nm as excitation
wavelength (Figure 1a), which was associated with 1.9 and 1.2 µs fluorescence lifetimes (τ) in the
case of LYZ- and BSA-Au NCs, respectively. The quantum yields (QY%) were ca. 4%. No plasmon
bands were identified in the UV-Vis spectra, which refers to the absence of larger plasmonic Au NPs.
The optical data strongly support the presence of ultrasmall protein-Au NCs [35].
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Figure 1. (a) The photoluminescence (PL) spectra of the lysozyme (LYZ)- and bovine serum albumin
(BSA)-gold nanoclusters (Au NCs) with the schematic illustration of protein-Au NCs and (b) the
representative high resolution transmission electron microscopic (HRTEM) images of the NCs with the
photos of the samples under a UV lamp.
After purifications, the dispersions contained ca. 80% of the initial gold amount, which was
determined by ICP-MS. To investigate the exact structure of these Au NCs, it was found that the NCs
were mostly built up from Au(0) because the 4f7/2 band was detected between 84.2–84.5 eV [36] on the
XPS spectra (Figure S1 in supplementary materials). The protein chains are stretched and unfolded due
to the cluster-formations, which has been verified by FT-IR and CD spectroscopy [37,38]. Based on the
HRTEM images (Figure 1b), the average diameter of the synthesized Au seed was ca. 1.4 nm depending
on the applied stabilizing protein. The kinetic stability of the Au NCs was determined based on DLS
and ζ-potential measurements using pH = 7.4 and 0.1 M ionic strength. The hydrodynamic diameters
were 5.0 ± 1.4 and 4.7 ± 1.8 nm using LYZ or BSA as stabilizing protein, respectively. Based on the
data, the hydrodynamic diameters are larger than the primer gold seeds based on HRTEM thanks to
the large protein shell. The ζ-potentials were −15.4 ± 2.7 and −26.4 ± 1.3 mV in the case of LYZ- and
BSA-Au NCs, respectively, which refers to the good kinetic stability of the clusters under physiological
conditions. To investigate the fluorescence behavior depending on the pH, it was determined that the
prepared Au NCs preserved their emission properties in a wide pH range. They lost their stability and
fluorescence only under extremely acidic conditions [29].
3.2. Characterization of Chit-HyA Drug Carrier NPs
The type II and type III carriers with different Chit:HyA mass ratios were successfully prepared
using the ionic gelation method and simple electrostatic interaction [10]. The formed NPs have two
different structures which are presented in Figure 2.
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Figure 2. (a) Schematic illustration of the preparation ways of chitosan-hyaluronic acid (Chit-HyA)
NPs and (b) representative dynamic light scattering (DLS) curves of type II and type III NPs with a
TEM image of type II NPs.
For type II, the simultaneous addition of TPP and HyA gave more compact NPs, with the
polysaccharides evenly distributed in the bulk phase. In the case of type III, the particles gained a
core-shell structure, with TPP cross-linked Chit core and HyA shell, where the large molecular weight
HyA polymer (approximately 6.6 times larger than Chit MW) could not penetrate the cross-linked,
compact Chit core, resulting in bigger NPs [10]. The size of the carriers was measured with DLS, and size
distribution was calculated from the results. Comparing the carriers with same composition (40:1
mChit:mHyA) the type III system was larger (dZ-average = 187.7 ± 2.5 nm, mean size was 186.4 ± 69.0 nm),
compared to type II with the same composition (dZ-average = 135.4 ± 3.6 nm, the mean size for
distribution calculations was 126.4 ± 40.6 nm), verifying the difference in structure. To evaluate the
stability and surface charge of the carriers, zeta potential measurements were made. The values
obtained from the samples were close to +11.9–13.3 mV in the synthesis buffer, which indicated that
the NPs were not very stable. After three dilutions of the samples, these values rose to +15.4–20.6 mV,
resulting in more stable suspensions. Furthermore, after cleaning the dispersions from the buffer with
centrifugation and then redispersing the NPs in ultrapure water, the zeta potential values increased
dramatically to +60–70 mV, showing that the stability of the nanocarriers is heavily dependent on
the matrix conditions (mainly pH and ionic strength). The loading of hydrophobic drug TCP into
the carriers slightly changed their properties, for example increased the overall charge of the NPs to
+14.2–20.6 mV, enhancing the stability of the dispersion in the synthesis matrix. Aside from this the
drug carriers could be used the same way as the empty NPs in the subsequent labeling process.
3.3. Evaluation of the Fluorescence Labeling with Au NCs
In order to determine the appropriate amount of the Au NCs for optimal labeling, a series of
samples with different Au NC:carrier mass ratios were prepared and investigated. The goal was to
examine the effect of the labeling on the size and stability of the carrier particles using DLS and zeta
potential measurements. The results for different carrier formulations and Au NCs are visualized in
Figure 3.
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Figure 3. Zeta potential values of the (a) BSA-Au NC-labeled and (b) LYZ-Au NC-labeled Chit/HyA
colloidal carriers (type II and III) as a function of Au NC:carrier mass ratios.
We observed that small amount of the NCs increases the Zeta potential values first in most cases,
then it decreases in the expected way. W can state that, d pending o the available polysacch rides
on the surf c of the carrier NPs and the type of Au NCs, the point of zero charge (ζ = 0 mV) can
be ob e ved at different mAuNC:mcarrier mass ratios. Compari g the titration results for the two
nanoclusters (Figure 3a,b), it was evident that more LYZ-Au NCs are necessary to neutralize all hree
examined dru carriers, most probably due to their lower charge (se Section 3.1). For type III with
10:1 Chit:HyA co eChit-shellHyA NPs, the charg neutralization occurs at 0.0648 mAuNC:mcarrier for
BSA-Au NC and at 0.1035 mAuNC:mcarrier for LYZ-Au NC, whi h means that ca. 60% more LYZ-Au
NC is required compared to BSA-Au NCs. For similar type NPs (type III) with 40:1 ratio (less HyA
content), 1.6 nd 2.0 more BSA- and LYZ-Au NCs can bind to the carrier NPs, r pectively (0.1064
mAuNC:mcarrier for BSA-Au NCs and 0.2091 mAuNC:mcarri r for LYZ-Au NCs). For type II carrie s,
the point of zero charge is at 0.1222 mAuNC:mcarrier for BSA-Au NCs and at 0.2548 mAuNC:mcarrier
fo LYZ-Au NC, which eans a 15% and 22% incre se in bound Au NCs quantity instead of type
III with the same 40:1 mass ratio. It can be concl ded that the protein-stabil zed BSA- and LYZ-Au
NCs having negative surf ce cha ge can bind better to the Chit HyA colloidal NPs if the carriers
are in “composite” form (type II) instead f core-shell type structu with negativ ly charged HyA
sh ll. This bservation clearly indicates the formation of electrostatic interaction between the colloidal
carrier and the protein-stabilized Au NCs.
Observing the changes in size throughout the labeling, we could see that the particle size
gradually increas d between the first additions of nanoclusters, here the z ta potential was relatively
l rge. Closer to the neutralization point the stability of the labeled systems rapidly decreased, which
manifested in the exponen ial i crease of the measured size well above 1 µm, and the particles also
pa tially aggregated when the Zeta pote tial was ~5 mV r lower. After neutralization, the dispersion
complete y aggregated, nd the Z ta potential became negative, indicating the presence of fr e Au NCs
in he system. Figure 4 shows the representativ siz distribution curves of type III olloidal c rri rs
with 40:1 Chit:HyA ratio label d with two different fluorescent clusters.
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3.3.1. Comparison of Different Labeling Techniques
Following the quantitative evaluation of the labeling, we tried to determine whether labeling
during or after carrier synthesis is the better method. For this experiment we chose different carrier-Au
NC compositions, and prepared the samples in the following sequence: for labeling after synthesis,
the Au NCs were added to the previously fabricated NPs under vigorous stirring. For simultaneous
labeling, the NCs were introduced during preparation, where they were mixed to the HyA-TPP mixture
(for type II) or to the TPP solution (for type III, during the Chit-TPPcore preparation step). From these
two methods, we expected two different structures to form: one with high Au NC content on the
surface, and one with the nanoclusters evenly distributed in the marked particle.
The results of these experiments showed that the two methods gave clearly different products,
and the difference was also visually perceptible. The postlabeled carriers were obviously larger in
size (ca. 30–40% higher), and even the turbidity of these dispersions was bigger. These observations
were also verified with DLS measurements, as shown in Figure 5. The particle size also increased
for simultaneous labeling (ca. 10–15% higher) compared to the bare drug carriers. Summarizing our
findings, we were able to choose which method was better for the fluorescent labeling. On the one
hand, the labeling during synthesis produced smaller particles, with the marker evenly distributed in
the entire nanocarrier. This means that normalizing for particle size, larger amounts of Au NCs could
be introduced to the system this way, but this method strongly changes the particle structure, thus its
encapsulation and drug release capabilities. Furthermore, large amounts of the nanoclusters became
unreachable with this method, which could hinder the release of drugs linked to the BSA or LYZ by
changing the tertiary structure of the proteins. This structural modification could also cause detrimental
effects on the fluorescence stability and intensity. On the other hand, the postlabeling method gave
larger particles with lower fluorescent marker density comparing same-sized NPs. The NCs were
situated on the surface of the labeled carrier, which has several advantages. First, the structure of both
the carrier and the fluorescent marker remained rather intact, which would mean fewer changes in
the encapsulation and release properties of the carrier and the proteins in the nanoclusters. With this
method, the initial fluorescence properties of the Au NCs could be better preserved as well. Thus,
we chose the labeling of the pre-formed colloidal NPs for the investigations on fluorescence.
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3.3.2. Labeling of Drug-Loaded Carriers
Continuing the investigation of drug carrier labeling, we examined whether the hydrophobic
model drug TCP could be introduced into this system without complications. First, we tested the
ethanol and TCP tolerance of the nanoclusters. In this experiment different amounts of ethanol or
TCP/ethanol solution was added to Au NC dispersions under stirring. The dispersion did not show
any changes to ethanol, no aggregation occurred even after adding twice the amount to the system.
In the case of TCP, only the drug formed particles in the Au NC dispersion due to the high water
content where TCP was insoluble, while the nanoclusters remained stable.
The nanocluster stability measurements allowed us to try preparing drug-loaded,
fluorescence-labeled complexes. The preparation methods were the same as mentioned before,
but the drug was added to the HyA-TPP or TPP solutions, accompanied by parallel fluorescent marking
of the fabricated samples. The final products showed good stability, no aggregation happened during
or after synthesis. These samples were also investigated by DLS. The results in Figure S2 further
proved that the drug loading only caused a small increase in particle size. Zeta potential measurements
also ascertained the stability of the NPs, with values around +19.4–23.6 mV. These results showed that
the fluorescent labeling of loaded carriers can be successfully carried out.
3.4. Fluorescence Measurements
3.4.1. Fluorescence Spectroscopy Studies
To quantify the effectiveness of the postlabeled syntheses, the emission intensities of the NCs
were measured by a simple spectr fluorime ric technique. In all cases, five individual ampl s were
prepar d based on the previously registered titration curves (Figure 3) in the case of the type II and the
ty e III (40:1) c mposites. After th measurements, the elative fluorescence (F/F0) was calculated by
using blank solutions, which contained the adequate amount of pr tein-Au NCs without the drug
carrier system under the same cond tions. The results can be seen on the Figure 6.
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Figure 6. The relative fluorescence of the postlabeled composites using BSA-Au NCs (a,b) and LYZ-Au
NCs (c,d).
Based on the measurements, it was found that more intensive fluorescence can be detected using
LYZ-Au NCs. As it c n b seen, in the case of e type II carrier system the measured intensity was
increased threefold, whil th F/F0 reached ca. 6.5 value at the type III delivery ystem. In contrast,
the BSA-Au NCs id not show any significant changes in he luminescent properties independently
from the chemical structure of the carriers. After a deeper study of the measured data, ome interesting
phenom na can be identified. On one hand, if we xamine the difference betwe n the same types of
carri rs, this growth can be du to the larger amount of the LYZ-Au NCs. As the la ger amount of
fluorescent object can lead to a decrease in the distance between the NCs, aggregation-induced emission
(AIE) can be realiz d [39]. Due to the s rongly inhib ted intramol cular rotations and vibrations,
the decrease of PL intensity does not occur. On the ot r ha d, the type of ca rier systems also ha
large effect on the det ct d intensi ies. Based on Se tion 3.2, the exact structur of the type III
drug carrier system was assigned. This well-defined Chit-TPPcore–HyAshell, which h s a large local
negativ charge excess on its surface, can bin much more LYZ-Au NCs on its surfac . The applied
pH (pH = 4.50) is close to th charge tran fer point of the stabilizer BSA, while the LYZ ha positive
charge ti l pH = 10.0 [29]. Based n this fact, most p obably the strength of the electrostatic interaction
between the LYZ-s abilized NCs as pot ntial FRs nd the drug delivery system having co e-shell
structure with negative surface charg is more dominant.
3.4.2. Fluorescence Microscopy Measurements
In the case of fluorescently labeled samples, it was important to determine whether the interaction
between the carrier and the Au NCs was strong, or the NCs could be washed off from the surface. It was
also necessary to figure out whether a minimal amount of NCs could provide enough fluorescence.
To resolve these questions, samples with no fluorescent arker and nes with few r many nanoclusters
(close to zero charge mass ratios) were put on microscope slides with a stamping method. This ay
allowed the fl orescent complexes (NPs or larger aggregates) to gather in the holes left by the sta i
fabric between its fibers, thus giving stronger fluorescence compared to normally prepared samples,
where t e particles are evenly distributed on t e slide. This method was appropriate for samples with
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no marker or close to zero charge, but, for carriers with few attached NCs, the aggregation effect was
not enough to detect any fluorescence. For these samples, the NPs were aggregated by adding more
NaOH solution to the labeled dispersions, this way more fluorescent NPs could be placed on the slides.
The results of the microscopy verified that the labeling was successful, as it can be seen in Figure 7
and Figures S3 and S4.
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Figure 7. Fluorescence microscopy images of BSA- (left) and LYZ- (right) Au NCs-labeled type III NPs
with 40:1 mass ratio (upper: addition of 50 µL NC dispersion; below: addition of 300 µL NC dispersion
mAu NC/mcarrier = 0.0215 (upper) and 0.1389 (below).
l ith no marker, no light emission was det cted, showing that the carrie NPs had no
detectable intr sic fluorescence. The carriers with few NCs gave minimal fluorescence (Figure 7 upper
images), as the stamping ethod could not accumul te the p rticles ve y well due to the hardened
structure of the aggregat s caused by the high pH. Nevertheless, the presenc of gold NCs linked to
the carriers could be verified, and even small amounts caused visibl emi sion. For labeled c rriers
lose to zero charge, the stamping could effectively in rease the fluoresc nce in certain positions,
theref re enabling us to better discern differences between each formulation. Compared to BSA-Au
NC, carriers m k d with LYZ-Au NC gave stronger emission in all cases, verifying the results of
the fluoresc nce spe trosco y. This effect could be a sed by the higher concent ation of LYZ-Au
NCs required for charge neut alization, so we compared the carriers using the same amount of both
NCs. We di cov red that the fluorescence intensity remained higher, so the LYZ-Au NCs performed
b tter in the label g experiments (Figur 7). This difference could be caused by the AIE effect, as
mentioned in the previous section [39]. Comparing our samples based on the carrier type, we could see
that some changes in fluorescence occurr d due t the different Chit:HyA mass ratios and structure .
For type III formulations, larger amounts of HyA meant that fewer Au NCs could be linked to th
carrier, meaning lower fluorescenc intensity. This amount could be increased with simultaneous
marking during fabrication, taking into considerat on the effects on the structure of both carrier and
Au NCs. The exchange of HyA wit NCs is also possible, but in this ca e the shell thickness would be
sacrificed for higher fluorescence intensity. However, it is also important to mention that using the
same amount of mark r for different c mpositions, the on s with m re HyA gave higher fluorescence,
but this effect also result d in the loss of particle stability and increase in size. Examini g type II and
III carriers with he same composition (Figures S3 and S4), we could se that the fluorescence was
more intensive for type III ca riers. This could b expl in d by the fact that the surface concentra ion
of HyA was higher for the core-shell type particles, and the proximity of the polysaccharide to the
NCs somehow ncreased the fluorescence int nsity, maybe du to HyA molecules inhibiting the
free movement of the clust r-stabilizing LYZ prot in. Th s could also explain why the high r HyA
concentrat on in type III carrie s caused stronger emission despite using equal amounts of nanoclusters.
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After successfully verifying the fluorescence of the complexes, we investigated the stability of the
interaction by washing the samples before or after the stamping. For the first method, the dispersions
were centrifuged, and then the carriers were redispersed in ultrapure water. The washed samples were
placed on the slides as described previously. For the other method, the samples dried on the slides
were wetted with ultrapure water to dissolve and to get rid of the buffer salts and other contaminants.
The water was removed from the glass, and the complexes were dried again. The samples washed both
ways showed satisfactory emission during measurements, meaning that the interaction between the
carriers and the nanoclusters was strong enough to retain the fluorescent properties of the complexes.
4. Discussion
Different protein-stabilized red-emitting Au NCs having same size and optical properties and
Chit-HyA drug carriers have been fabricated to investigate whether their interaction could lead to
fluorescently labeled complex systems. DLS and zeta potential measurements clearly proved the size,
good size distribution and adequate stability of the prepared systems in both cases. Then, the Chit-HyA
colloid carrier systems were titrated with the nanocluster aqueous dispersions, and the resulting
complex dispersions were evaluated using DLS, zeta potential, fluorimetry and fluorescent microscopy
studies. Based on the quantitative charge titration measurements we established that the carriers
having more HyA molecules closer to the particle surface (either because of larger HyA content or
different structure) could bind less Au NCs, losing their stability sooner. From this point of view,
the type II with 40:1 Chit:HyA ratio could be labeled with the most fluorescent NCs. Comparing
the two gold NCs, more LYZ-Au NCs were necessary for charge neutralization, therefore stronger
fluorescence could be reached with these. Fluorescence spectroscopy and microscopy helped us in
visualizing the actual emission properties of the complexes. Our findings gave similar results with
both techniques, further proving the superiority of LYZ-Au NCs, because higher emission intensity
could be reached with these, even using the same NC concentrations. As for the carriers, the ones with
higher HyA concentration near the surface showed stronger fluorescence with LYZ-Au NCs despite the
lower Au NC concentration, probably due to the AIE effect. Based on these facts, for a good labeling
reaction the NC content has to be precisely controlled to reach high fluorescence, while also keeping
the particle size and stability in check.
The next step in our work was to evaluate two different labeling methods: adding the fluorescent
marker during or after synthesis. While both methods have their own advantages and drawbacks,
the postlabeling allows fewer NCs to be bound to the carrier particles, but, this way, the structure,
and thus the encapsulation and release properties of the two components, as well as the freedom of Au
NCs, could be better retained.
The last part of our investigation was to determine whether the labeling works for drug loaded
carriers or not. We concluded that the labeling method was capable of producing small, stable fluorescent
drug loaded nanocarriers, which could be used in further pharmaceutical or medical applications.
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Figure S1. Representative XPS spectra of (a) LYZ-Au NC and (b) BSA-Au NC, Figure S2: Representative DLS
curves of type III NPs labeled with (a) BSA-Au NC or (b) LYZ-Au NC, with the blank (black), labeled (red) and
labeled, drug-loaded carriers (green), Figure S3: Fluorescence microscopy images of BSA- (left) and LYZ- (right)
Au NCs-labeled type III NPs with 10:1 mass ratio (upper: addition of 50 µL NC dispersion; below: addition of 140
µL NC dispersion cAu = 0.0163 (upper) and 0.0615 (below)), Figure S4: Fluorescence microscopy images of BSA-
(left) and LYZ- (right) Au NCs-labeled type II NPs with 40:1 mass ratio (upper: addition of 50 µL NC dispersion;
below: addition of 350 µL NC dispersion cAu = 0.0215 (upper) and 0.1621 (below)).
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